Ingenol Mebutate
This topical gel is derived from the Euphorbia peplus plant and is used to treat actinic keratoses, precancerous skin lesions caused by sun damage. It works through two mechanisms: direct necrosis of abnormal skin cells and stimulation of a local immune response that clears residual abnormal cells. Treatment involves applying the gel for only 2-3 consecutive days.
Peso molecular
430,5000 g/mol
LogP
2,00
TPSA
104,00 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C
InChI
InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1
Molecular Formula
C25H34O6
HBD / HBA
3 / 6
Enlaces Rotables
4
Átomos Pesados
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This topical gel is derived from the Euphorbia peplus plant and is used to treat actinic keratoses, precancerous skin lesions caused by sun damage. It works through two mechanisms: direct necrosis of abnormal skin cells and stimulation of a local immune response that clears residual abnormal cells. Treatment involves applying the gel for only 2-3 consecutive days.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Ingenol Mebutate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1863513. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918670. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ingenol-mebutate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ingenol-mebutate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ingenol-mebutate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ingenol-mebutate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ingenol-mebutate"></drugfyi-drug>